# Complications of MitraClip 

Jung-Sun Kim, MD, Ph D, FESC<br>Division of Cardiology, Severance Hospital Yonsei University College of Medicine

# Disclosure Information Jung-Sun Kim, MD, PhD 

- Grants/Research Support: None
- Support/Consultant: None
- Speaker's Bureau: Abbott Vascular


## Procedure-related

| Access-site |  | Bleeding | Ischemic |
| :---: | :---: | :---: | :---: |
| Vascular <br> Dissection Stenosis Aterial/venous thrombosis Perforation Rupture | Cardiac iASD <br> Atrial/ventricle perforation Pericardial effusion Tamponade Pseudoaneurysm | Access-site <br> Gastrointestinal <br> Urinary tract Pericardial effusion Central venous line Aterial line Obscure bleeding | Myocardial Infarction Stroke Acute thrombus formation |
|  | Arrhythmia | Renal | Infectious |
|  | New-onset atrial fibrillation | Acute Kidney Injury | Endocarditis |

Schnitzler K, et al. Curr Cardiol Rep 2021;23:131

## Relatively Safe Procedure !!!

Real-world data show a very low intraprocedural (TRAMI registery $0.1 \%$, Praz et al. 0\%, Chakravarty et al. 0\%) and in-hospital mortality (TRAMI 2.4\%, TCVT 2.9\%, German nationwide sample 3.6\%, TVT 2.7\%, NIS database 2.0\%).

The latest studies with the XTR/NTR and "G4" reported an even lower in-hospital mortality (XTR/NTR 0.9\%, G4 0\%)

Schnitzler K, et al. Curr Cardiol Rep 2021;23:131

# Cardiac Tamponade 

## Incidence: 0-0.5 \%



Aggravated dyspnea with GDMT
Atrial fibrillation
Severe Pul. HTN

Very severe MR due to flail AML (A3 and P3, commissural) due to ruptured chordae

Yonsei University College of Medicine



Intercomissural
LVOT





Severance Cardiovascular Hospital
Q


## Management of Cardiac Tamponade

- Immediate emergency pericardiocentesis if necessary.
- In case with puncture with only needle, immediate reversal of therapeutic anticoagulation and removal of the needle may be adequate.
- If the guide catheter or other equipment has been advanced over the needle and out into the pericardial space, it is important to not immediately remove them once the problem is recognized. Consideration should be made for surgical removal of the larger bore catheters at this point and in select clinical and anatomic cases closure devices can be considered.


## Air or Thrombombolic Events

## Incidence : 3-7 \% (cardiac and cerebrovascular events)

## Management of Air Embolism

- Manifest as stroke, coronary ischemia (esp, RCA territory), and cardiac arrest.
- Extra care with aspiration and flushing of the transseptal equipment, the MitraClip guide and delivery system.
- Adequate oxygenation, hemodynamic support with intravenous fluids and pressors when necessary, mechanical aspiration.


## Management of Acute thrombus formation

- "Wait and see" strategy with readministration of heparin, thrombus aspiration, or low-dose thrombolysis considering of bleeding risk.

SCAI Textbook Transcatheter Edge-to-Edge Repair
Schnitzler K, et al. Curr Cardiol Rep 2021;23:131

## Leaflet Injury/Chordal Entanglement Incidence : 0-2 \%

## M/82 AMI with stenting, PeAF



LVEDD/ESD: 60/46mm, LAVI: 62ml/m2, EF: 51\%, E/e':15, RVSP :41mmHg


## Intraprocedural TEE



## Pre Grasping



## Intraprocedural TEE



Pre Grasping


## Intraprocedural TEE



Failed to grasp a central portion of MV (A2-P2 due to chordae rupture)


Firstly, grasping medial part with $1^{\text {st }}$ Clip


Then, grasping central part with $2^{\text {nd }}$ Clip

## Before and After MitraClip



## Management of Chordal Entanglement

1. Assessing the device trajectory considering chordae structure and direction
2. Adjusting device orientation before valve crossing - Don't rotate $>\mathbf{1 5}$ degree within the ventricle.
3. Avoiding excessive opening or premature deployment of device apparatus
4. Disentangle device - reverse the set of movements
5. Eversion with 270 degree angle and retraction into the atrium

F/79, PeAF, s/p PTCA c stent
TTE


Severe MR
(GIV, ERO: 33 mm², RV: 61 ml ) Poor leaflet coaptation with annular flattening
Moderate TR

EF: 63\%, LVEDD/ESD: 56/40 mm, LAVi: $86 \mathrm{ml} / \mathrm{m}^{2}$, RVSP: 61 mmHg

## TEE



TEER - After deployment of the $1^{\text {st }}$ clip with several attempts


## TEER - Several attempts with $\mathbf{2}^{\text {nd }}$ clip

XT -> XTW


Yonsei University College of Medicine

## TEER - Final TEE



Increased MR d/t MV leaflet tear and unstable vital sign $\rightarrow$ Emergent MV replacement

## Prevention of leaflet damage

- Excessive tension should be avoided in case with long clip and annular calcification
- An important measure of caution is a slight advancement of the clip in ventricular direction during clip closure.
- The hypothesis of an increased risk for XTR to injure the leaflets due to the longer arms with a higher force on the leaflet per area.
- An effective bailout maneuver can be to grasp the injured leaflet further at the base either by a different device position or with a device with longer clip arms.

Schnitzler K, et al. Curr Cardiol Rep 2021;23:131

## Mitral Stenosis

## How to reduce mitral gradient ?

- Reposition MitraClip with less tissue grasped -> reduce the tension on the leaflets.
-> This should be done with caution and not at the expense of safe tissue grasped to avoid SLDA
- Reposition MitraClip with a more lateral placement to the jet
- Use NT instead of XT

Once the clip is released, gradients may potentially decrease by up to $\mathbf{2 0 \%}$.

If residual MR is significant, this may drive the transmitral gradient falsely higher due to increased flow across the valve.

## SLDA and Embolization

## What is the cause of SLDA and Clip embolization ?

Continuous reduction in SLDA over years, which likely reflects the implanter's learning curve and advances in the clip systems: EVEREST I 11.0\%, EVEREST II 5.1\%, ACCESSEU 4.8\%, TRAMI 2.0\%, TVT 1.5\%, Praz et al. 4.0\%, Mitra EXPAND 1.9\%, and "G4" 1.7\%

Only two studies, the TCVT and TVT, describe clip embolization in $0.7 \%$ and $0.1 \%$ Right axillar artery, renal artery and apex of the LV.

Success rate of re-intervention with TEER: Around 25-50 \%

| CAUSE FOR SLDA | SPECIFIC EXPLANATION |
| :--- | :--- |
| Inadequate leaflet capture | - Poor echo imaging ${ }^{21}$ <br> - Short leaflet (NTR $<6 \mathrm{~mm}, \mathrm{XTR}<9 \mathrm{~mm}$ ) <br> - Gripper below leaflet |
| Poor tissue quality | - Thin leaflet ${ }^{13}$ <br> - Connective tissue disorder ${ }^{15}$ |
|  | - Myxomatous leaflet <br> - Steroid use ${ }^{23}$ |
| Excessive clip-leaflet tension | - Calcified leaflet or annulus ${ }^{7}$ |
| - Severe mitral annular dilation ${ }^{12}$ |  |
| - Use of individual grippers and aggressive anterior or posterior torque |  |
| - Cardioversion ${ }^{23}$ |  |

## M/80 PeAF, ESRD on HD

## Pre-procedural TTE

ERO: 38mm ${ }^{2}$ RV: 73cc

LA AP : 54 mm LVEDD : 63mm


Severe MR and Rreduced LV systolic function (EF 51\%), considering the degree of MR

## Pre-procedural TEE



Severe MR, Thickened and Tethered MV

Yonsei University College of Medicine

## Intraprocedural TTE



After leaflet grasped at lateral side and mild residual MR was seen and MDPG was 4 mmHg , XT device system was finally released

## Coronary angiography



PCI was done at pLCx
due to
significant stenosis
after Clipping



4 monthsatier TEER


## Post-procedural TTE



Mitral Clipping device was located at A\&P 1-2 portion of MV
Decreased MR

## TTE at 4 months after TEER



Single leaflet detachment at AML
Increased to severe MR

## F/84 PeAF, TTE



## TEE



Severe MR (GIV/IV) d/t annular dilatation ( 53.6 mm ) and overriding AML and tethering PML

## MitraClip Procedure



## TTE POD \#1



MDPG: 3.4 mmHg
Markedly decreased MR

## Fluoroscopy (POD \#15)



## TEE (POD \#33)



Increased MR (GIII-IV/IV)

## Re-do MitraClip \& Retrieval of embolized clip (POD \#34)



## Re-do MitraClip \& Retrieval of embolized clip (POD \#34)



Successful retrieval of embolized mitraclip with 16 Fr sheath and double snaring method

## Summary

1. Appropriate plans and target goals are needed for difficult cases.
2. To reduce complications, operators have to be aware of these adverse events and their risk factors and be familiar with their prophylaxis and bailout options.
3. Further improvement of devices and experience of operator should be warranted to reduce complications.

## Severance

## With the Love of God, Free Humankind from Disease and Suffering



